# Corcept Therapeutics Incorporated (CORT)

Source: https://www.quantisnow.com/company/CORT
Generated: 2026-11-09T00:05:22.999Z

- Ticker: CORT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2004
- SEC CIK: 0001088856
- Website: corcept.com

## About

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

## Latest CORT news and filings

- 2026-11-05 00:26 UTC [SEC Form 4] [Maduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,046,351 worth of shares (25,000 units at $81.85) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/maduck-sean-exercised-25000-shares-at-a-strike-of-827-6773816)
- 2026-11-05 00:20 UTC [SEC Form 4] [President, Oncology Vieira Roberto Wandenkolk exercised 8,333 shares at a strike of $21.63 and sold $674,069 worth of shares (8,333 units at $80.89) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-oncology-vieira-roberto-wandenkolk-exercised-8333-shares-at-a-6773814)
- 2026-11-03 21:11 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Corcept Therapeutics Incorporated](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-corcept-therapeutics-incorporated-6769703)
- 2026-11-03 21:09 UTC [SEC Form 8-K] [Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/corcept-therapeutics-incorporated-filed-sec-form-8-k-results-of-operations-6769644)
- 2026-11-03 21:05 UTC [Earnings] [Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/corcept-therapeutics-announces-third-quarter-financial-results-and-provides-corporate-6769477)
- 2026-10-27 20:05 UTC [Earnings Date] [Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call](https://www.quantisnow.com/insight/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-6759114)
- 2026-10-26 12:00 UTC [Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer](https://www.quantisnow.com/insight/corcept-reports-positive-results-from-phase-2-bella-trial-of-6757057)
- 2026-10-20 20:00 UTC [2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes](https://www.quantisnow.com/insight/2026-adaeasd-consensus-report-recommends-screening-for-hypercortisolism-in-patients-6752033)
- 2026-10-16 22:24 UTC [SEC Form 4] [Director Wilson James N sold $1,148,083 worth of shares (10,000 units at $114.81) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-wilson-james-n-sold-1148083-worth-of-shares-10000-6749640)
- 2026-10-05 23:58 UTC [SEC Form 4] [President, Oncology Vieira Roberto Wandenkolk sold $967,448 worth of shares (8,333 units at $116.10) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-oncology-vieira-roberto-wandenkolk-sold-967448-worth-of-shares-6737808)
- 2026-10-05 23:54 UTC [SEC Form 4] [Officer Lyon Joseph Douglas sold $1,160,731 worth of shares (10,000 units at $116.07) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-lyon-joseph-douglas-sold-1160731-worth-of-shares-10000-6737804)
- 2026-10-05 23:49 UTC [SEC Form 4] [Officer Maduck Sean sold $2,906,601 worth of shares (25,000 units at $116.26) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-maduck-sean-sold-2906601-worth-of-shares-25000-units-6737798)
- 2026-10-05 23:44 UTC [SEC Form 4] [SEC Form 4 filed by Corcept Therapeutics Incorporated](https://www.quantisnow.com/insight/sec-form-4-filed-by-corcept-therapeutics-incorporated-6737792)
- 2026-10-05 23:18 UTC [SEC Form 3] [SEC Form 3 filed by Corcept Therapeutics Incorporated](https://www.quantisnow.com/insight/sec-form-3-filed-by-corcept-therapeutics-incorporated-6737773)
- 2026-09-28 20:30 UTC [SEC Form 4] [Chief Business Officer Robb Gary Charles gifted 17,100 shares and received a gift of 10,000 shares, decreasing direct ownership by 55% to 14,056 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-robb-gary-charles-gifted-17100-shares-and-6727870)
- 2026-09-23 12:15 UTC [SEC Form 8-K] [Corcept Therapeutics Incorporated filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/corcept-therapeutics-incorporated-filed-sec-form-8-k-regulation-fd-disclosure-6723708)
- 2026-09-23 12:00 UTC [Leadership Update] [Corcept Announces Planned Leadership Transition](https://www.quantisnow.com/insight/corcept-announces-planned-leadership-transition-6723656)
- 2026-09-18 23:53 UTC [SEC Form 4] [President, Oncology Vieira Roberto Wandenkolk sold $29,843 worth of shares (296 units at $100.82) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 3,946 units (SEC Form 4)](https://www.quantisnow.com/insight/president-oncology-vieira-roberto-wandenkolk-sold-29843-worth-of-shares-6720995)
- 2026-09-18 23:47 UTC [SEC Form 4] [Chief Business Officer Robb Gary Charles exercised 17,493 shares at a strike of $8.27, increasing direct ownership by 128% to 31,156 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-robb-gary-charles-exercised-17493-shares-at-6720988)
- 2026-09-18 12:00 UTC [Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)](https://www.quantisnow.com/insight/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-6720042)
- 2026-09-16 20:30 UTC [SEC Form 4] [Officer Lyon Joseph Douglas exercised 10,000 shares at a strike of $12.99 and sold $1,134,947 worth of shares (10,000 units at $113.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-lyon-joseph-douglas-exercised-10000-shares-at-a-strike-6717703)
- 2026-09-16 20:30 UTC [SEC Form 4] [Director Wilson James N sold $1,106,940 worth of shares (10,000 units at $110.69) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-wilson-james-n-sold-1106940-worth-of-shares-10000-6717702)
- 2026-09-04 23:15 UTC [Leadership Update] [Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600](https://www.quantisnow.com/insight/bloom-energy-illumina-and-everpure-set-to-join-sp-500-6707090)
- 2026-09-04 01:16 UTC [SEC Form 4] [Chief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-guyer-william-was-granted-328-shares-increasing-6706046)
- 2026-09-04 01:16 UTC [SEC Form 4] [Officer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/officer-maduck-sean-covered-exercisetax-liability-with-117-shares-exercised-6706044)
- 2026-09-04 01:06 UTC [SEC Form 4] [Chief Financial Officer Mokari Atabak covered exercise/tax liability with 102 shares and was granted 276 shares, increasing direct ownership by 1% to 16,304 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-financial-officer-mokari-atabak-covered-exercisetax-liability-with-102-6706043)
- 2026-09-04 01:03 UTC [SEC Form 4] [Chief Business Officer Robb Gary Charles was granted 328 shares and covered exercise/tax liability with 91 shares, increasing direct ownership by 2% to 13,663 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-business-officer-robb-gary-charles-was-granted-328-shares-6706040)
- 2026-09-04 01:02 UTC [SEC Form 4] [President, Oncology Vieira Roberto Wandenkolk was granted 276 shares, covered exercise/tax liability with 102 shares, exercised 58,333 shares at a strike of $21.63 and sold $6,460,766 worth of shares (58,333 units at $110.76) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 4,242 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/president-oncology-vieira-roberto-wandenkolk-was-granted-276-shares-covered-6706039)
- 2026-09-04 01:00 UTC [SEC Form 4] [Officer Lyon Joseph Douglas was granted 260 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 3% to 5,683 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/officer-lyon-joseph-douglas-was-granted-260-shares-and-covered-6706036)
- 2026-09-04 00:39 UTC [SEC Form 3] [New insider Vieira Roberto Wandenkolk claimed ownership of 4,068 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-vieira-roberto-wandenkolk-claimed-ownership-of-4068-shares-6706027)
- 2026-08-28 20:30 UTC [SEC Form 4] [Director Park Kimberly exercised 30,000 shares at a strike of $13.49, covered exercise/tax liability with 3,315 shares and sold $3,270,169 worth of shares (26,685 units at $122.55) (SEC Form 4)](https://www.quantisnow.com/insight/director-park-kimberly-exercised-30000-shares-at-a-strike-of-6698520)
- 2026-08-27 20:30 UTC [SEC Form 4] [Officer Maduck Sean exercised 30,955 shares at a strike of $11.35 and sold $3,887,320 worth of shares (30,955 units at $125.58) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-maduck-sean-exercised-30955-shares-at-a-strike-of-6697313)
- 2026-08-20 20:30 UTC [SEC Form 4] [Director Mahoney David L sold $12,251,411 worth of shares (103,606 units at $118.25) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-mahoney-david-l-sold-12251411-worth-of-shares-103606-6690199)
- 2026-08-18 20:30 UTC [SEC Form 4] [Director Wilson James N sold $1,114,261 worth of shares (10,000 units at $111.43) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-wilson-james-n-sold-1114261-worth-of-shares-10000-6686820)
- 2026-08-18 20:30 UTC [SEC Form 4] [Chief Business Officer Robb Gary Charles sold $1,162,572 worth of shares (10,000 units at $116.26) and gifted 125 shares, decreasing direct ownership by 0.92% to 13,426 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-robb-gary-charles-sold-1162572-worth-of-6686818)
- 2026-08-18 20:30 UTC [SEC Form 4] [Officer Maduck Sean exercised 3,664 shares at a strike of $8.27 and sold $419,491 worth of shares (3,664 units at $114.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-maduck-sean-exercised-3664-shares-at-a-strike-of-6686817)
- 2026-08-18 12:22 UTC [Analyst Coverage Resumed] [Truist resumed coverage on Corcept Therapeutics with a new price target](https://www.quantisnow.com/insight/truist-resumed-coverage-on-corcept-therapeutics-with-a-new-price-6685969)
- 2026-08-14 20:31 UTC [SEC Form 4] [Chief Business Officer Robb Gary Charles gifted 11,530 shares and received a gift of 6,000 shares, decreasing direct ownership by 46% to 13,551 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-robb-gary-charles-gifted-11530-shares-and-6683277)
- 2026-08-13 20:20 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Corcept Therapeutics Incorporated](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-corcept-therapeutics-incorporated-6680734)
- 2026-08-12 20:27 UTC [SEC Form 4] [Officer Maduck Sean exercised 1,031 shares at a strike of $8.27 and sold $118,068 worth of shares (1,031 units at $114.52) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-maduck-sean-exercised-1031-shares-at-a-strike-of-6678148)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CORT
- Earnings history: https://www.quantisnow.com/earnings/CORT
- Dividend history: https://www.quantisnow.com/dividends/CORT
- Insider transactions: https://www.quantisnow.com/insiders/CORT
- Options chain: https://www.quantisnow.com/options/CORT
- SEC 8-K filings only: https://www.quantisnow.com/company/CORT/8-k
- RSS and alerts for CORT: https://www.quantisnow.com/docs/rss-feeds.md